eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Phase III prospective randomized trial of dose-escalated radiotherapy with or without short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
    Adjuvant radiotherapy
  3. Intervention
  4. Intervention
    External-beam radiation therapy
  5. Intervention
    Androgen-deprivation therapy
  6. Intervention
    Androgen antagonists
  7. Intervention
    Antineoplastic agents, hormonal
  8. Resource Description
    RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Androgens can cause the growth of prostate cancer cells. Androgen-deprivation therapy may lessen the amount of androgens made by the body. It is not yet known whether radiation therapy is more effective with or without androgen-deprivation therapy in treating patients with prostate cancer. PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with androgen-deprivation therapy in treating patients with prostate cancer.
  9. Contact
    Berenberg, Jeffrey
  10. PI
    Berenberg, Jeffrey
  11. Topic
    prostate cancer
  12. Study Population
    Males aged 18 and older with histologically confirmed adenocarcinoma of the prostate diagnosed within the past 6 months and at intermediate-risk for recurrence.
  13. Website(s)
  14. Phase
    Phase 3 clinical trial
  15. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016